[Cardiovascular diseases, antiplatelet agents, anticoagulants and hemorrhagic risk].
If the benefits of antiplatelet and anticoagulant therapies are well established, bleeding complications appear underestimated in trials in comparison to their real-life incidence. Also, a large number of patients receive various associations of antiplatelet or anticoagulant treatments, while the benefit of some associations is not firmly established and data about their safety are missing. Identifying patients at high risk of bleeding is essential to define appropriate strategies. In this article we discuss the risk-benefit of various antiplatelet and anticoagulant molecules taken individually or in combination. An overview of the main clinical scores available to stratify the risk of bleeding is presented.
Service de médecine interne générale, Département de médecine interne, HUG, 1211 Genève 14. Jorge.Eusebio@hcuge.ch
Jorge
J
Eusébio
Jean-Luc
JL
Reny
Pierr
P
Fontana
Mathieu
M
Nendaz
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D020521:Stroke / Q000517:prevention & control*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors